The FDA has accepted the resubmitted BLA for linvoseltamab for patients with relapsed/refractory multiple myeloma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback